FY-EM4436 Mouse D2D(D-Dimer) ELISA Kit

D2D(D-Dimer) Basic information

D-dimer is a fibrin degradation product (or FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. It is so named because it contains two D fragments of the fibrin protein joined by a cross-link, hence forming a protein dimer. D-dimer concentration may be determined by a blood test to help diagnose thrombosis. Since its introduction in the 1990s, it has become an important test performed in people with suspected thrombotic disorders, such as venous thromboembolism. While a negative result practically rules out thrombosis, a positive result can indicate thrombosis, but does not exclude other potential causes. Its main use, therefore, is to exclude thromboembolic disease where the probability is low.

Mouse D2D(D-Dimer) ELISA Kit test method

This kit was based on Competitive-ELISA detection method. The microtiter plate provided in this kit has been pre-coated with target. During the reaction, target in the sample or standard competes with a fixed amount of target on the solid phase supporter for sites on the Biotinylated Detection Antibody specific to target. Excess conjugate and unbound sample or standard are washed from the plate, and HRP-Streptavidin (SABC) is added to each microplate well and incubated. Then TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm. The concentration of target in the samples is then determined by comparing the OD of the samples to the standard curve.

Reference:

1. Asakura, Hidesaku; Ogawa, Haruhiko (2020). "COVID-19-associated coagulopathy and disseminated intravascular coagulation". International Journal of Hematology. 113 (1): 45–57. doi:10.1007/s12185-020-03029-y. ISSN 0925-5710. PMC 7648664. PMID 33161508.

2. Khan, Faizan; Tritschler, Tobias; Kahn, Susan R; Rodger, Marc A (2021). "Venous thromboembolism". The Lancet. doi:10.1016/s0140-6736(20)32658-1. ISSN 0140-6736. PMID 33984268.

3. Ponti, G; Maccaferri, M; Ruini, C; Tomasi, A; Ozben, T (2020). "Biomarkers associated with COVID-19 disease progression". Critical Reviews in Clinical Laboratory Sciences. 57 (6): 389–399. doi:10.1080/10408363.2020.1770685. ISSN 1040-8363. PMC 7284147. PMID 32503382.